Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$-- Mln
Revenue (TTM)
$-- Mln
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
3.6
Industry P/E
--
EV/EBITDA
-1.4
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
54,493,100
CFO
€-235.00 Mln
EBITDA
€-284.39 Mln
Net Profit
€-256.21 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Pharvaris BV (PHVS)
| -10.0 | 23.2 | 2.4 | -15.2 | 1.1 | -- | -- |
|
BSE Sensex*
| 4.4 | 4.0 | 7.8 | 10.4 | 14.6 | 21.5 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
Pharvaris BV (PHVS)
| 149.3 | -21.8 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Pharvaris BV (PHVS)
|
17.3 | 909.5 | 0.0 | -141.0 | -- | -49.9 | -- | 3.6 |
| 0.1 | 3.0 | 0.9 | -70.0 | -7,823.0 | -241.9 | -- | 0.2 | |
| 0.1 | 9.4 | 48.5 | -35.5 | -117.5 | 397.6 | -- | 0.9 | |
| 4.3 | 871.4 | 537.3 | 200.0 | 48.5 | 28.1 | 4.8 | 1.1 | |
| 1.8 | 112.5 | 0.1 | -44.7 | -35,719.4 | -65.9 | -- | 1.4 | |
| 1.3 | 32.9 | 5.2 | -28.0 | -451.1 | -95.4 | -- | 1.2 | |
| 1.8 | 180.1 | 19.0 | -30.2 | -157.4 | -58.1 | -- | 1.9 |
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a... small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland. Address: Grafenauweg 8, Zug, Switzerland, 6300 Read more
Co-Founder, CEO & Executive Director
Mr. Berndt Axel Edvard Modig CPA, M.B.A.
Co-Founder, CEO & Executive Director
Mr. Berndt Axel Edvard Modig CPA, M.B.A.
Headquarters
Zug
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Pharvaris BV (PHVS) stood at $ 357 Mln as on 31-Mar-25
The share price of Pharvaris BV (PHVS) is $17.25 (NASDAQ) as of 20-May-2025 16:00 EDT. Pharvaris BV (PHVS) has given a return of 1.09% in the last 3 years.
Pharvaris BV (PHVS) has a market capitalisation of $ 909 Mln as on 20-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Pharvaris BV (PHVS) is 3.62 times as on 20-May-2025, a 28% premium to its peers’ median range of 2.83 times.
Since, TTM earnings of Pharvaris BV (PHVS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Pharvaris BV (PHVS) and enter the required number of quantities and click on buy to purchase the shares of Pharvaris BV (PHVS).
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland. Address: Grafenauweg 8, Zug, Switzerland, 6300
The CEO & director of Mr. Berndt Axel Edvard Modig CPA, M.B.A.. is Pharvaris BV (PHVS), and CFO & Sr. VP is Mr. Berndt Axel Edvard Modig CPA, M.B.A..
There is no promoter pledging in Pharvaris BV (PHVS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
73
|
|
|
36
|
|
|
15
|
|
|
4
|
|
|
3
|
|
|
1
|
|
|
73
|
|
|
36
|
|
|
15
|
| Pharvaris BV (PHVS) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Pharvaris BV (PHVS) was $0 Mln.
$0.56
(
